Combo Therapy for Advanced NSCLC Provides PFS Benefit

The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed.

Key Takeaway

• In patients with epidermal growth factor receptor (EGFR) TP53-mutated non–small cell lung cancer (NSCLC), combining a tyrosine kinase inhibitor (TKI) with antiangiogenic therapy or chemotherapy led to better progression-free survival (PFS) than a TKI alone.

Why This Matters

• Typically, these patients have a poor prognosis.

• Adding an antiangiogenic agent or chemotherapy to TKI therapy may prolong the PFS in this patient population.

Study Design

• The study included 124 patients with advanced NSCLC as well as EGFR and TP53 mutations from a single center in China.

• Overall, 72 patients received EGFR-TKIs combined with antiangiogenic drugs (22 patients) or chemotherapy (50 patients). Among those who were given an antiangiogenic agent, 12 received anlotinib, and 10 received bevacizumab.

• The remaining 52 patients underwent EGFR-TKI monotherapy.

• The primary endpoint was PFS.

Key Results

• The median PFS was significantly longer in the combination therapy group (18.0 months vs 7.0 months; P < .001).

• In the combination group, 89% of patients were alive and progression-free at the 6-month mark, compared with 71% in the EGFR-TKI group.

• At 12 months, the rates were 62% in the combination group and 24% in the monotherapy group.

Limitations

• The study was retrospective, and few patients had BRAC1 and MYC mutations compared with other mutations

• The authors used a single accrual center for data collection.

• The study did not report adverse effects, owing to incomplete medical records.

Disclosures

• The study was supported by the National Natural Science Foundation of China.

• The authors did not report any conflicts of interest.

This is a summary of a preprint research study, "Optimal Therapy for Concomitant EGFR and TP53 Mutated Non–Small Cell Lung Cancer: A Real-world Study." The study has not been peer reviewed. The full text can be found at researchsquare.com.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Cite this: Combo Therapy for Advanced NSCLC Provides PFS Benefit - Medscape - Dec 19, 2022.